Skip to main content

Safir Anand and Vaishali Sharma share their views.

The issue of regulating online sale of drugs by e-pharmacies has been grabbing much attention in the last few years, especially in past one year, since the introduction of Draft Rules in August 2018.

As per the Madras HC Order in December last year, the government was to finalise the Draft Rules by January 31, 2019 which was later extended to July 31st.

Through the introduction of these Rules, an attempt is being made to ensure that e-pharmacy portals comply with substantive laws and obtain valid registrations apart from following prescribed procedure for online sale of drugs.

In fact, in June, a meeting was held between Ministry of Health, Department of Pharmaceuticals along with the officials of the Niti Aayog, the Drug Controller General and key stakeholders discussing several aspects involved while finalizing the Draft Rules.

Even though these Draft Rules mandate requirement of a prescription, the format of prescription that may be permissible still remains a key issue for consideration. This is so, as currently, e-pharmacy apps allow users to merely upload a snapshot of a written prescription, which in actual, may even be fake, tampered, modified or repeated as opposed to uploading a valid e-prescription or electronic version received from prescribing doctors directly.

Concerning the cases against e-pharmacies, in March this year, a PIL was withdrawn in Calcutta High Court and very recently, on August 7, in a PIL filed in the Bombay High Court, the Court has terminated the proceedings noting the Centre’s confirmation to release final notification on Draft Rules by December this year.

Meanwhile, in the Delhi High Court, in a plea seeking contempt action against the e-pharmacies for continuing to sell drugs online despite the DHC Order in December last year staying such activity, the e-pharmacies and Centre have sought time to file their reply and the matter is now listed for September 24, 2019.

In December last year, the Madras High Court had suspended their Order banning online sale of drugs upon an appeal filed by e-pharma companies.

With the recent developments in this arena, both the Indian Government as well as Courts appear to be positive towards regularizing the ever-growing e-pharmacy industry, but with a watch dog over them. However, much depends upon as to how soon these Draft Rules are notified in the Official Gazette and the manner of their implementation, which is to be seen in the days to come.

Also, from the perspective of trademarks law, there is ample reason to consider the liability of an e-Pharmacy for wrong dispersion of medicines, as well as any issues relating to spurious, misbranded and sub-standard drugs and also counterfeit or look alike medicines.

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Sep 02, 2026

Author: Lakshmidevi Somanath The law currently provides creators exclusive rights over their creation for a limited time, which gives a human inventor

From Innovation Incentives to Technology Diffusion – Protection of Intellectual Property Created by Agentic Artificial Intelligence
News & Updates, Thought Leadership
Aug 30, 2026

I. The Infringer’s Privacy Paradox The Digital Personal Data Protection Act, 2023 (“DPDP Act”) is built around a clear rule. Personal data

The DPDP Act’s Unanswered Question: Can Privacy Law Block a Software Piracy Investigation?
News & Updates, Thought Leadership
Aug 28, 2026

‘First published on India Business Law Journal’ By: Pravin Anand, Ajai Garg and Siddhant Chamola The Supreme Court of India’s Artificial Intelligence

Keeping the ‘judge’ in judgment
News & Updates, Thought Leadership
Aug 05, 2026

‘First published on Asia IP’ By: Safir Anand and Ritu Bhargava India has taken important steps forward in protecting consumers who use its digital

Misleading ads and dark patterns: Evolving jurisprudence in India